Gordon Waldron
Président chez Antabio SAS
Profil
Gordon Waldron is currently the Chairman at Antabio SAS.
He previously worked as the Finance Director at Texas Instruments Incorporated, Director at Neorphys SAS, Controller at Spie Batignolles SAS, Chief Financial Officer at Synt:em SA, and Chief Financial Officer at Novexel SA. From 2010 to 2015, he served as the CFO, Executive VP & Head-Investor Relations at SuperSonic Imagine SA. Mr. Waldron obtained his undergraduate degree from Duke University in 1988.
Postes actifs de Gordon Waldron
| Sociétés | Poste | Début |
|---|---|---|
Antabio SAS
 Antabio SAS Pharmaceuticals: MajorHealth Technology Antabio SAS operates as a biopharmaceutical company which develops drugs for the treatment and prevention of antibiotic-resistant bacterial infections. The firm focuses bacterial disease research, drug design, antibiotic combination testing, and in vitro technology development operations. The company was founded by Marc Lemonnier and Aymeric Dugray on October 15, 2009 and is headquartered in Labege, France. | Président | - |
Anciens postes connus de Gordon Waldron
| Sociétés | Poste | Fin |
|---|---|---|
| SUPERSONIC IMAGINE | Directeur Financier/CFO | 15/04/2015 |
Neorphys SAS
 Neorphys SAS Pharmaceuticals: MajorHealth Technology Founded in September 2005 by Dr Roger LAHANA, CEO, and Karine LARBOURET, Director of Operations, Neorphys is a company which discovers and develops novel, proprietary analgesic drug candidates with low side effects, especially with regard to gastro-intestinal transit. This is why the most advanced drug candidate is developed for visceral pain management. Beside the co-founders, Neorphys scientists, all PhD's or equivalent, share a strong expertise in opioids and acute pain as well as in behavioral pharmacology. They have a proven track record of success in using discovery techniques such as medicinal chemistry, cell biology, toxicology and relevant animal assays. | Directeur/Membre du Conseil | 11/03/2014 |
Spie Batignolles SAS
 Spie Batignolles SAS Engineering & ConstructionIndustrial Services Spie Batignolles SA provides construction services. It specializes in engineering, civil works, sanitation, maintenance, and remodeling solutions for commercial buildings and industrial projects. The company was founded in 1968 and is headquartered in Neuilly-sur-Seine, France. | Comptroller/Controller/Auditor | - |
| TEXAS INSTRUMENTS INCORPORATED | Directeur Financier/CFO | - |
Novexel SA
 Novexel SA Pharmaceuticals: MajorHealth Technology Novexel SA researches and develops anti-infective drugs for the treatment of bacterial and fungal infections. The firm focuses on discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The company was founded in December 2004 and is headquartered in Romainville, France. | Directeur Financier/CFO | - |
Formation de Gordon Waldron
| Duke University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| TEXAS INSTRUMENTS INCORPORATED | Electronic Technology |
| Entreprise privées | 6 |
|---|---|
Spie Batignolles SAS
Spie Batignolles SAS Engineering & ConstructionIndustrial Services Spie Batignolles SA provides construction services. It specializes in engineering, civil works, sanitation, maintenance, and remodeling solutions for commercial buildings and industrial projects. The company was founded in 1968 and is headquartered in Neuilly-sur-Seine, France. | Industrial Services |
Synt:em SA
 Synt:em SA Pharmaceuticals: MajorHealth Technology Synt:em SA researches and manufactures drugs for the treatment of pain and cancer. The company specializes in the discovery and development of Central Nervous System (CNS) medicines and novel therapeutics for the treatment diseases. It was founded in 1995 by Michel Kaczorek and Caroline Roussel and is headquartered in Nîmes, France. | Health Technology |
Novexel SA
Novexel SA Pharmaceuticals: MajorHealth Technology Novexel SA researches and develops anti-infective drugs for the treatment of bacterial and fungal infections. The firm focuses on discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The company was founded in December 2004 and is headquartered in Romainville, France. | Health Technology |
SuperSonic Imagine SA
 SuperSonic Imagine SA Medical SpecialtiesHealth Technology SuperSonic Imagine SA specializes in ultrasound medical imaging. The company designs, develops and markets a new generation ultrasound system, Aixplorer with an UltraFastTM platform that can acquire images faster than conventional ultrasound systems. Its products are used for general imaging, vascular, hepatology, gastroenterology, and research procedures. It operates under the Aixplorer trademark. SuperSonic Imagine was founded by Jacques Souquet, Armen Sarvazyan, Claude Cohen-Bacrie, Damien Dolimier, Georges Charpak, Jérémy Bercoff, Mickaël Tanter, Mathias Fink and Marianne Leven on March 10, 2005 and is headquartered in Aix-en-Provence, France. | Health Technology |
Neorphys SAS
Neorphys SAS Pharmaceuticals: MajorHealth Technology Founded in September 2005 by Dr Roger LAHANA, CEO, and Karine LARBOURET, Director of Operations, Neorphys is a company which discovers and develops novel, proprietary analgesic drug candidates with low side effects, especially with regard to gastro-intestinal transit. This is why the most advanced drug candidate is developed for visceral pain management. Beside the co-founders, Neorphys scientists, all PhD's or equivalent, share a strong expertise in opioids and acute pain as well as in behavioral pharmacology. They have a proven track record of success in using discovery techniques such as medicinal chemistry, cell biology, toxicology and relevant animal assays. | Health Technology |
Antabio SAS
Antabio SAS Pharmaceuticals: MajorHealth Technology Antabio SAS operates as a biopharmaceutical company which develops drugs for the treatment and prevention of antibiotic-resistant bacterial infections. The firm focuses bacterial disease research, drug design, antibiotic combination testing, and in vitro technology development operations. The company was founded by Marc Lemonnier and Aymeric Dugray on October 15, 2009 and is headquartered in Labege, France. | Health Technology |
